Ikaria has acquired the exclusive worldwide license to Fibrex Medical’s portfolio of investigational compounds, for a range of critical care conditions.
The investigational compounds – FX06, FX201, and FX107 are fibrin-derived peptides. They bind to vascular endothelial cells, preserving endothelial barrier function and preventing tissue injury.
Reportedly, Fibrex Medical will receive upfront and milestone payments, as well as royalties on net sales. Ikaria will be responsible for pre-clinical and clinical development activities, as well as commercialization.
Daniel Tasse, president and CEO of Ikaria, said: Acquiring the global license to the Fibrex portfolio is consistent with our mission to deliver therapies which address the significant unmet needs of the millions of patients who are hospitalized with serious conditions caused or complicated by vascular leakage and resulting extravasion and tissue injury.
Rainer Henning, president and CEO of Fibrex Medical, said: We are proud of the pipeline we have built around our completely novel mechanism of action and very excited to enter into this agreement with Ikaria to complete development and commercialization. We are delighted to partner with Ikaria with its unwavering commitment to delivering novel therapies to critically ill patients around the world.